Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
NCT05011266Phase 3Recruiting
- Sponsor
- New York State Psychiatric Institute
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid use disorder (OUD) comparing Buprenorphine-naloxone with Placebo (2 arms). Primary endpoint: Proportion of participants receiving XR-naltrexone injections at 20 weeks. Started Apr 2023; status: recruiting.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05011266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011266.